UCB's medicines are making a real difference to the lives of patients all over the world. Our products are among the leaders in their field. UCB focuses on several main therapeutic areas, immunology, neurology and rare diseases.
Our medicines
The following UCB medicines are currently available in Canada. Provided below are the current approved Product Monographs, including Patient Medical Information.
Canadian laws and regulations limit the amount of information we can provide to the general public about prescription drug products. We encourage patients and consumers wishing to obtain more detailed information on our products to consult a qualified healthcare professional.
The product information on this web site is intended for residents of Canada only.
Search all products
Neurology and rare diseases
Brivlera®
Brivlera® (brivaracetam) Product Monograph
24-September-2024 | PDF file
Neurology and rare diseases
Keppra®
Keppra® (levetiracetam) Product Monograph
7-March-2023 | PDF file
Neurology and rare diseases
Neupro®
Neupro® (rotigotine transdermal patch) Product Monograph
10-March-2021 | PDF file
Immunology
Rystiggo®
Rystiggo® (rozanolixizumab injection) Product Monograph
25-April-2025 | PDF file
Neurology and rare diseases
Vimpat®
Vimpat® (lacosamide) Product Monograph
15-September-2022 | PDF file
Neurology and rare diseases
Zilbrysq®
Zilbrysq® (zilucoplan injection) Product Monograph
11-July-2024 | PDF
Note:
- Cimzia®, Keppra®, Brivlera®, Bimzelx® are registered trademarks of the UCB Group of Companies
- Neupro® is a registered trademark used under license from UCB Pharma GmbH
- Vimpat® is a registered trademark used under license from Harris FRC Corporation
- Zilbrysq® is a registered trademark of Ra Pharmaceuticals, Inc.
The information cited on this website is for Canada only. The medicinal products mentioned here are not approved for sale in all markets worldwide. Moreover, currently registered indications of said products may differ from country to country. Therefore, physicians should always consult local prescribing information. Patients should always consult their physician for information regarding these medicinal products.
As part of our commitment to responsible medication [medical sharps] disposal, we are proud to support Medications Return Programs [and/or Sharps Collection Programs] managed by Health Products Stewardship Association (HPSA). These programs provide a safe and convenient way for consumers to dispose of unused or expired household medications (medical sharps) in an environmentally responsible manner.
To learn more about properly storing and handling pharmaceuticals and medical sharps or finding a collection location near you, we encourage you to visit the HPSA website at www.healthsteward.ca.
